L. Chaperot, M. Delfau-larue, M. Jacob, J. Molens, B. Roussel et al., Differentiation of antitumor-specific cytotoxic T lymphocytes from autologous tumor infiltrating lymphocytes in non-Hodgkin???s lymphomas, Experimental Hematology, vol.27, issue.7, pp.1185-93, 1999.
DOI : 10.1016/S0301-472X(99)00057-0

G. Maass, W. Schmidt, M. Berger, F. Schilcher, F. Koszik et al., Priming of tumor-specific T cells in the draining lymph nodes after immunization with interleukin 2-secreting tumor cells: three consecutive stages may be required for successful tumor vaccination., Proceedings of the National Academy of Sciences, vol.92, issue.12, pp.5540-5544, 1995.
DOI : 10.1073/pnas.92.12.5540

R. Zinkernagel, S. Ehl, P. Aichele, S. Oehen, T. Kundig et al., Antigen localisation regulates immune responses in a dose- and time-dependent fashion: a geographical view of immune reactivity, Immunological Reviews, vol.131, issue.1, pp.199-209, 1997.
DOI : 10.1016/S0167-5699(96)10066-9

A. Ochsenbein, P. Klenerman, U. Karrer, B. Ludewig, M. Pericin et al., Immune surveillance against a solid tumor fails because of immunological ignorance, Proceedings of the National Academy of Sciences, vol.96, issue.5, pp.2233-2241, 1999.
DOI : 10.1073/pnas.96.5.2233

G. Dunn, A. Bruce, H. Ikeda, L. Old, and R. Schreiber, Cancer immunoediting: from immunosurveillance to tumor escape, Nature Immunology, vol.3, issue.11, pp.991-999, 2002.
DOI : 10.1038/ni1102-991

J. Unkeless, Function and heterogeneity of human Fc receptors for immunoglobulin G., Journal of Clinical Investigation, vol.83, issue.2, pp.355-61, 1989.
DOI : 10.1172/JCI113891

D. Schmitt, D. Hanau, T. Bieber, C. Dezutter-dambuyant, D. Schmitt et al., Human epidermal Langerhans cells express only the 40- kilodalton Fcg receptor (FcRII), J Immunol, vol.144, pp.4284-90, 1990.

N. Fanger, K. Wardwell, L. Shen, T. Tedder, and P. Guyre, Type I (CD64) and type II (CD32) Fc gamma receptormediated phagocytosis by human blood dendritic cells, J Immunol, vol.157, pp.541-549, 1996.

J. Ravetch and R. Clynes, RECEPTORS AND COMPLEMENT IN VIVO, Annual Review of Immunology, vol.16, issue.1, pp.421-453, 1998.
DOI : 10.1146/annurev.immunol.16.1.421

A. Regnault, D. Lankar, V. Lacabanne, A. Rodriguez, C. Thery et al., Fc?? Receptor???mediated Induction of Dendritic Cell Maturation and Major Histocompatibility Complex Class I???restricted Antigen Presentation after Immune Complex Internalization, The Journal of Experimental Medicine, vol.70, issue.2, pp.371-80, 1999.
DOI : 10.1084/jem.184.3.863

M. Albert, S. Pearce, L. Francisco, B. Sauter, P. Roy et al., and CD36, and Cross-present Antigens to Cytotoxic T Lymphocytes, The Journal of Experimental Medicine, vol.265, issue.7, pp.1359-68, 1998.
DOI : 10.1126/science.270.5241.1500
URL : https://hal.archives-ouvertes.fr/pasteur-01402441

S. Nair, A. Buiting, R. Rouse, N. Van-rooijen, L. Huang et al., Role of macrophages and dendritic cells in primary cytotoxic T lymphocyte responses, International Immunology, vol.7, issue.4, pp.679-88, 1995.
DOI : 10.1093/intimm/7.4.679

P. Machy, K. Serre, and L. Leserman, Class I-restricted presentation of exogenous antigen acquired by Fc?? receptor-mediated endocytosis is regulated in dendritic cells, European Journal of Immunology, vol.30, issue.3, pp.848-57, 2000.
DOI : 10.1002/1521-4141(200003)30:3<848::AID-IMMU848>3.0.CO;2-Q

F. Villinger, A. Mayne, P. Bostik, K. Mori, P. Jensen et al., Evidence for Antibody-Mediated Enhancement of Simian Immunodeficiency Virus (SIV) Gag Antigen Processing and Cross Presentation in SIV-Infected Rhesus Macaques, Journal of Virology, vol.77, issue.1, pp.10-24, 2003.
DOI : 10.1128/JVI.77.1.10-24.2003

S. Stager, A. J. Kirby, A. Botto, M. Rooijen, N. Smith et al., Natural antibodies and complement are endogenous adjuvants for vaccine-induced CD8+ T-cell responses, Nature Medicine, vol.9, issue.10, pp.1287-92, 2003.
DOI : 10.1038/nm933

R. Dyall, L. Vasovic, R. Clynes, and J. Nikolic-zugic, Cellular requirements for the monoclonal antibody-mediated eradication of an established solid tumor, European Journal of Immunology, vol.66, issue.1, pp.30-37, 1999.
DOI : 10.1002/(SICI)1521-4141(199901)29:01<30::AID-IMMU30>3.0.CO;2-D

U. Galili, E. Rachmilewitz, A. Peleg, and I. Flechner, A unique natural human IgG antibody with anti-alpha-galactosyl specificity, Journal of Experimental Medicine, vol.160, issue.5, pp.1519-1550, 1984.
DOI : 10.1084/jem.160.5.1519

U. Galili, B. Macher, J. Buehler, and S. Shohet, Human natural anti-alpha-galactosyl IgG. II. The specific recognition of alpha (1----3)-linked galactose residues, Journal of Experimental Medicine, vol.162, issue.2, pp.573-82, 1985.
DOI : 10.1084/jem.162.2.573

U. Galili, Interaction of the natural anti-Gal antibody with ??-galactosyl epitopes: a major obstacle for xenotransplantation in humans, Immunology Today, vol.14, issue.10, pp.480-482, 1993.
DOI : 10.1016/0167-5699(93)90261-I

U. Galili, R. Mandrell, R. Hamahdeh, S. Shohet, and J. Griffis, Interaction between human natural anti-a-galactosyl immunoglobulin G and bacteria of the human flora, Infect Immun, vol.56, pp.1730-1737, 1988.

U. Galili, M. Clark, S. Shohet, J. Buehler, and B. Macher, Evolutionary relationship between the natural anti-Gal antibody and the Gal alpha 1----3Gal epitope in primates., Proceedings of the National Academy of Sciences, vol.84, issue.5, pp.1369-73, 1987.
DOI : 10.1073/pnas.84.5.1369

U. Galili, S. Shohet, E. Kobrin, C. Stults, and B. Macher, Man, apes, and Old World monkeys differ from other mammals in the expression of a-galactosyl epitopes on nucleated cells, J Biol Chem, vol.263, pp.17755-62, 1988.

B. Collins, A. Cotterell, K. Mccurry, C. Alvarado, J. Magee et al., Cardiac xenografts between primate species provide evidence for the importance of the a-galactosyl determinant in hyperacute rejection, J Immunol, vol.154, pp.5500-5510, 1995.

R. Unfer, D. Hellrung, C. Link, and . Jr, Immunity to the a(1,3)galactosyl epitope provides protection in mice challenged with colon cancer cells expressing a(1,3)galactosyl-transferase: a novel suicide gene for cancer gene therapy, Cancer Res, vol.63, pp.987-93, 2003.

D. Latemple, T. Henion, F. Anaraki, and U. Galili, Synthesis of a-galactosyl epitopes by recombinant a1,3 galactosyltransferase for opsonization of human tumor cell vaccines by anti-galactose, Cancer Res, vol.56, pp.3069-74, 1996.

U. Galili and D. Latemple, Natural anti-Gal antibody as a universal augmenter of autologous tumor vaccine immunogenicity, Immunology Today, vol.18, issue.6, pp.281-286, 1997.
DOI : 10.1016/S0167-5699(97)80024-2

J. Plumas, L. Chaperot, M. Jacob, J. Molens, C. Giroux et al., Malignant B lymphocytes from non-Hodgkin's lymphoma induce allogeneic proliferative and cytotoxic T cell responses in primary mixed lymphocyte cultures: An important role of co-stimulatory molecules CD80 (B7-1) and CD86 (B7-2) in stimulation by tumor cells, European Journal of Immunology, vol.179, issue.12, pp.3332-3373, 1995.
DOI : 10.1002/eji.1830251220

L. Chaperot, M. Chokri, M. Jacob, P. Drillat, F. Garban et al., Differentiation of antigen-presenting cells (dendritic cells and macrophages) for therapeutic application in patients with lymphoma, Leukemia, vol.14, issue.9, pp.1667-77, 2000.
DOI : 10.1038/sj.leu.2401888

D. Latemple, J. Abrams, S. Zhang, and U. Galili, Increased immunogenicity of tumor vaccines complexed with anti- Gal: studies in knockout mice for a1,3galactosyltransferase, Cancer Res, vol.59, pp.3417-3440, 1999.

U. Galili, J. Buehler, S. Shohet, and B. Macher, The human natural anti-Gal IgG. III. The subtlety of immune tolerance in man as demonstrated by crossreactivity between natural anti-Gal and anti-B antibodies, Journal of Experimental Medicine, vol.165, issue.3, pp.693-704, 1987.
DOI : 10.1084/jem.165.3.693

T. Henion, B. Macher, F. Anaraki, and U. Galili, Defining the minimal size of catalytically active primate ??1,3 galactosyltransferase: structure-function studies on the recombinant truncated enzyme, Glycobiology, vol.4, issue.2, pp.193-201, 1994.
DOI : 10.1093/glycob/4.2.193

Z. Chen, M. Tanemura, and U. Galili, Synthesis of ??-gal epitopes (Gal??1-3Gal??1-4GlcNAc-R) on human tumor cells by recombinant ??1,3galactosyltransferase produced in Pichia pastoris, Glycobiology, vol.11, issue.7, pp.577-86, 2001.
DOI : 10.1093/glycob/11.7.577

M. Irisarri, J. Plumas, T. Bonnefoix, M. Jacob, C. Roucard et al., Resistance to CD95-mediated apoptosis through constitutive c-FLIP expression in a non-Hodgkin???s lymphoma B cell line, Leukemia, vol.14, issue.12, pp.2149-58, 2000.
DOI : 10.1038/sj.leu.2401954

K. Rafiq, A. Bergtold, and R. Clynes, Immune complex???mediated antigen presentation induces tumor immunity, Journal of Clinical Investigation, vol.110, issue.1, pp.71-80, 2002.
DOI : 10.1172/JCI0215640
URL : http://www.ncbi.nlm.nih.gov/pmc/articles/PMC151032

F. Manca, D. Fenoglio, L. Pira, G. Kunkl, A. Celada et al., Effect of antigen/antibody ratio on macrophage uptake, processing, and presentation to T cells of antigen complexed with polyclonal antibodies, Journal of Experimental Medicine, vol.173, issue.1, pp.37-48, 1991.
DOI : 10.1084/jem.173.1.37

K. Dhodapkar, J. Krasovsky, B. Williamson, and M. Dhodapkar, Antitumor Monoclonal Antibodies Enhance Cross-Presentation of Cellular Antigens and the Generation of Myeloma-specific Killer T Cells by Dendritic Cells, The Journal of Experimental Medicine, vol.6, issue.1, pp.125-158, 2002.
DOI : 10.1002/eji.1830270206

U. Galili, P. Repik, F. Anaraki, K. Mozdzanowska, G. Washko et al., Enhancement of antigen presentation of influenza virus hemagglutinin by the natural human anti-Gal antibody, Vaccine, vol.14, issue.4, pp.321-329, 1996.
DOI : 10.1016/0264-410X(95)00189-8

F. Ossendorp, E. Mengede, M. Camps, R. Filius, and C. Melief, Specific T Helper Cell Requirement for Optimal Induction of Cytotoxic T Lymphocytes against Major Histocompatibility Complex Class II Negative Tumors, The Journal of Experimental Medicine, vol.70, issue.5, pp.693-702, 1998.
DOI : 10.1084/jem.184.3.863